How to use Onkotaxel:

Onkotaxel  is a cytotoxic anticancer drug and, as with other potentially toxic compounds, caution should be exercised when handling and preparing Onkotaxel solutions. The use of gloves is recommended. If Onkotaxel  initial diluted solution, or final dilution for infusion should come into contact with the skin, immediately and thoroughly wash with soap and water. If Onkotaxel, initial diluted solution, or final dilution for infusion should come into contact with mucosa, immediately and thoroughly wash with water. Contact of the Onkotaxel with plasticized PVC equipment or devices used to prepare solutions for infusion is not recommended. In order to minimize patient exposure to the plasticizer DEHP (di-2-ethylhexyl phthalate), which may be leached from PVC infusion bags or sets, the final Onkotaxel dilution for infusion should be stored in bottles (glass, polypropylene) or plastic bags (polypropylene, polyolefin) and administered through polyethylene-lined administration sets.

One-vial Onkotaxel

Onkotaxel requires NO prior dilution with a diluent and is ready to add to the infusion solution. Please follow the preparation instructions provided below. Onkotaxel (20 mg/mL) requires NO prior dilution with a diluent and is ready to add to the infusion solution. Use only a 21 gauge needle to withdraw Onkotaxel from the vial because larger bore needles (e.g., 18 and 19 gauge) may result in stopper coring and rubber particulates.

If a dose greater than 200 mg of Onkotaxel  is required, use a larger volume of the infusion vehicle so that a concentration of 0.74 mg/mL Onkotaxel is not exceeded. Thoroughly mix the infusion by gentle manual rotation. As with all parenteral products, Onkotaxel should be inspected visually for particulate matter or discoloration prior to administration whenever the solution and container permit. If the Onkotaxel dilution for intravenous infusion is not clear or appears to have precipitation, it should be discarded.

Onkotaxel infusion solution is supersaturated, therefore may crystallize over time. If crystals appear, the solution must no longer be used and shall be discarded. The Onkotaxel dilution for infusion should be administered intravenously as a 1-hour infusion under ambient room temperature (below 25°C) and lighting conditions.